Sure we like to have a little fun here and there but this time I’ll be serious

Sure, we like to have a little fun here and there, but this time, I’ll be serious. Many of us have been affected in some way by the flooding that has been up and down the Mississippi River Growing up in St. Louis, I remember having to drink the crappy A-B white canned water back in ‘93 for the entire summer, and I thought that was bad enough, until today. If you haven’t seen the destruction by the flooding in Winfield, Mo this morning, it’s nasty.Imagine, sirens going off at 5:30a telling you to get the hell out of town because your house is about to get destroyed. No time to save anything other than yourself and maybe a family member or two. You could go to another house…but they’re leaving because their house is about to be demolished as well No warning No hope.It’s time that we get involved in some way You can donate to the American Red Cross, St Louis Chapter, which is the closest to Winfield $1, $5, $10. Large donations would be great, but many small ones are awesome too You at least have a home These people have nothing Here is the link to donate.

If you live close to Winfield, you can donate your time, which is more valuable than any sort of cash donation. But for those of us that don’t live close, please donate.And we’re closing in on two months until kickoff. I imagine it can’t come soon enough for all the sandbaggers and residents affected by these floods It’s right around the corner, and stay strong.Thanks.. UPPSALA, Sweden–(Business Wire)–Q-Med AB and Oceana Therapeutics, LLC., based in the US, have announced enteringinto definitive agreements to license worldwide commercialization rights toDeflux® and Solesta. The agreements also include future products that utilizeQ-Med`s proprietary NASHA technology. As part of the transaction Oceana Therapeutics is acquiring Q-Med Scandinavia,Inc., which accounts for the majority of the business for Deflux and Solesta.Included in this transaction are the exclusive rights to market, sell anddistribute Deflux and Solesta and other products intended for the management ofurological and gastroenterological conditions worldwide.

Q-Med will continue todevelop and manufacture all products under this agreement. Oceana will focus oncontinued global commercialization of Deflux and Solesta. Under the terms of the agreement Oceana will make an initial payment of $60million for the shares of Q-Med Scandinavia, Inc. and an additional payment of$15 million upon the US approval of Solesta. Under the agreements, if certainsales targets are achieved, Q-Med AB may receive additional milestone paymentsof up to $45 million.

Oceana will also pay a royalty for the licensing rightsbased on the net sales of the products. The parties will share the clinicaldevelopment cost for Solesta. Deflux is used for the treatment of VUR – a malformation of the urinary bladderwhich affects children and can give severe infections of the urinary tract andeven irreversible kidney damage. Treatment with Deflux is simple to perform andhas a rapid effect The largest single market for Deflux is the USA Around 1percent of all children born suffer from VUR.

In many cases it disappears byitself as the child gets older. This can, however, take many years and in themeantime often long-term treatment with antibiotics is carried out. Experienceshows at the same time that knowledge of VUR is poor and that up to 40 percentof the children affected never get referred to a specialist .Deflux representsthe only minimally invasive FDA approved alternative to major ureteralreimplantation surgery. Deflux is also used for other indications outside of theUnited States. Worldwide net sales of Deflux in 2008 were about $30 million. Solesta is approved for use in Europe and Canada as an injectable treatment forfecal incontinence, a condition which afflicts millions of patients. Fecalincontinence is considered a debilitating health problem that affects about 2percent of the general population and is four times more common in women than inmen.